Liquiritigenin targets transferrin receptor to potentiate ferroptosis sensitivity in colorectal cancer cells - PubMed
4 hours ago
- #Liquiritigenin
- #Colorectal Cancer
- #Ferroptosis
- Liquiritigenin (LIQ) identified as a ferroptosis sensitizer in colorectal cancer (CRC) cells.
- LIQ stabilizes transferrin receptor (TFRC) by inhibiting its ubiquitination and degradation.
- Stabilization of TFRC leads to increased intracellular iron and lipid peroxidation, sensitizing cells to ferroptosis.
- LIQ synergizes with ferroptosis inducers (sulfasalazine or RSL3) to suppress tumor growth in vivo and ex vivo.
- Highlights LIQ's potential as a dietary intervention in CRC therapy.